Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Natalia V. Vostokova"'
Autor:
Elena A. Merkulova, Dmitriy S. Gorchakov, Oleg D. Mitkin, Nataliya A. Penchul, Alina N. Egorova, George E. Rupchev, Allan G. Beniashvily, Denis S. Burminskiy, Lala N. Kasimova, Ruben N. Karapetian, Natalia V. Vostokova, Lubov Y. Gluskina, Olga A. Bukhanovskaya, Margarita A. Morozova, Taissia A. Lepilkina, Dmitry V. Kravchenko, Andrey Alexandrovich Ivashchenko, Sergey S. Potanin, Alexandre V. Ivachtchenko
Publikováno v:
Journal of psychiatric research. 143
Generalized anxiety disorder (GAD) is associated with an imbalance in the functioning of the stimulating neurotransmitter systems in human's brain. We studied the safety and therapeutic efficacy of aviandr, the new noradrenergic and specific serotone
Autor:
Elena A Smolyarchuk, Natalia V. Vostokova, Andrew A. Blinow, Elena V Yakubova, Ruben N. Karapetian, Elena G. Tikhomolova, Nikolay Filippovich Savchuk, Tagir A. Sitdekov, Elena A. Merkulova, Kirill A. Dmitriev, Elena N Simakina, Elena P. Pavlikova, Valeria N Azarova, Natalia A. Papazova, Andrey Alexandrovich Ivashchenko, Alexandre V. Ivachtchenko, Alina N. Egorova, Nikita V. Lomakin, Dmitry V. Kravchenko, Alexey P. Ilin, Ivan G. Gordeev
Publikováno v:
Clinical Infectious Diseases
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-
Autor:
Ivan G. Gordeev, Andrey Alexandrovich Ivashchenko, Alexey P. Ilin, Dmitry V. Kravchenko, Nikolay Filippovich Savchuk, Kirill A. Dmitriev, Nikita V. Lomakin, Elena V Yakubova, Ruben N. Karapetian, Elena G. Tikhomolova, Elena N Simakina, Elena A. Merkulova, Natalia V. Vostokova, Natalia A. Papazova, Elena A Smolyarchuk, Alexandre V. Ivachtchenko, Andrew A. Blinow, Elena P. Pavlikova, Tagir A. Sitdekov, Alina N. Egorova, Valeria N Azarova
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee4c74b1b527e94b4d82f6b1475524f5
Autor:
Oleg D. Mitkin, Natalia A. Shevkun, Dmitry V. Kravchenko, Ruben N. Karapetian, Mark S. Veselov, Yan A. Ivanenkov, Elena A. Bulanova, Angela G. Koryakova, Irina V. Kuznetsova, Vadim V. Bichko, Alexandre V. Ivachtchenko, Andrey S. Trifelenkov, Nina V. Chufarova, Natalia V. Vostokova, Pavel M. Yamanushkin
Publikováno v:
Journal of medicinal chemistry. 57(18)
A series of next in class small-molecule hepatitis C virus (HCV) NS5A inhibitors with picomolar potency containing 2-pyrrolidin-2-yl-5-{4-[4-(2-pyrrolidin-2-yl-1H-imidazol-5-yl)buta-1,3-diynyl]phenyl}-1H-imidazole cores was designed based on the SAR